Phase 1 Metastatic Solid Tumor trials recruiting now

All Metastatic Solid Tumor trials, every phase

Other phases for Metastatic Solid Tumor

Phase 1 Metastatic Solid Tumor trials

• A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
  NCT06244771 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
  NCT06657144 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
  NCT07172802 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Study of IDP-001 in Advanced or Metastatic Solid Tumors
  NCT07602842 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study of KK2269 in Adult Participants With Solid Tumors
  NCT06266299 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 32 locations
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
  NCT06561685 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
  NCT06465069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
  NCT06440005 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
  NCT05824975 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
  NCT06975410 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
  NCT07284186 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
  NCT04977453 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
  NCT05856981 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
  NCT06171750 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
  NCT05898399 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
  NCT06545942 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
  NCT06974110 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT06666270 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 154 locations

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.